MDM2 Degrader as a Promising Therapeutic Strategy for Cancer Treatment

MDM2, a key negative regulator of the tumor suppressor p53, has emerged as a compelling therapeutic target in human cancer. This Viewpoint summarizes the discovery of a potent and orally bioavailable MDM2 degrader that demonstrates unprecedented single dose antitumor efficacy. The compound holds substantial potential as a cancer therapeutic and warrants thorough preclinical evaluation.